Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1002/jca.21830

http://scihub22266oqcxt.onion/10.1002/jca.21830
suck pdf from google scholar
32875601!ä!32875601

suck abstract from ncbi


Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32875601      J+Clin+Apher 2021 ; 36 (1): 179-182
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Therapeutic plasma exchange in a critically ill Covid-19 patient #MMPMID32875601
  • Altmayer V; Saheb S; Rohaut B; Marois C; Cao A; Gallo A; Le Guennec L; Weiss N; Demeret S
  • J Clin Apher 2021[Feb]; 36 (1): 179-182 PMID32875601show ga
  • Here we describe the effect of therapeutic plasma exchange with 5% albumin as sole replacement solution for the management of Covid-19. A 74-year-old man was admitted for severe Covid-19 acute respiratory distress syndrome. Based on the growing body of evidence that cytokine release syndrome, and especially interleukin-6, plays a key role in critically ill Covid-19 patients, we decided to implement therapeutic plasma exchange as a rescue therapy. The patient's clinical status rapidly improved, and biological records showed convincing results of decrease in interleukin-6 and inflammatory parameters under treatment. This case presents a proof-of-concept for the use of therapeutic plasma exchange with 5% albumin as sole replacement solution in a critically ill Covid-19 patient with cytokine release syndrome. This could constitute a major benefit in terms of security compared to long-lasting immunosuppressive monoclonal antibodies, or to therapeutic plasma exchange with plasma as replacement fluid. Hence, we think that a further evaluation of risk-benefit balance of this therapy in severe cases of Covid-19 should rapidly be undertaken.
  • |*Plasma Exchange[MESH]
  • |*SARS-CoV-2[MESH]
  • |Aged[MESH]
  • |Albumins[MESH]
  • |C-Reactive Protein/analysis[MESH]
  • |COVID-19/*complications[MESH]
  • |Combined Modality Therapy[MESH]
  • |Critical Illness/*therapy[MESH]
  • |Cytokine Release Syndrome/blood/etiology/*therapy[MESH]
  • |Fibrinogen/analysis[MESH]
  • |Humans[MESH]
  • |Interleukin-6/blood[MESH]
  • |Male[MESH]
  • |Oxygen Inhalation Therapy[MESH]
  • |Oxygen/blood[MESH]
  • |Pneumonia, Ventilator-Associated/etiology[MESH]
  • |Respiration, Artificial/adverse effects[MESH]
  • |Respiratory Distress Syndrome/blood/etiology/therapy[MESH]
  • |Salvage Therapy[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box